Tudor Investment Corp
SMMT icon

Tudor Investment Corp’s Summit Therapeutics SMMT Stock Holding History

Tudor Investment Corp’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-384,988
Closed -$6.83M – 4217
2026
Q1 		$7.3M Sell
384,988
-38,096
-9% -$616K 0.01% 936
2025
Q4 		$7.4M Buy
423,084
+75,843
+22% +$1.43M 0.01% 917
2025
Q3 		$7.17M Buy
+347,241
New +$8.42M 0.01% 954
2023
Q3 		– Sell
-32,103
Closed -$80.6K – 2816
2023
Q2 		$80.6K Buy
32,103
+16,988
+112% +$31K ﹤0.01% 2307
2023
Q1 		$26K Buy
+15,115
New +$41.2K ﹤0.01% 2304

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Tudor Investment Corp's SMMT Position: Q2 2026 in Review

Tudor Investment Corp sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 384,988 shares — an estimated $6.83M sold.

Tudor Investment Corp first reported a position in SMMT in Q1 2023 and held it in 5 quarters. The position peaked at $7.4M in Q4 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Tudor Investment Corp reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Tudor Investment Corp sold 384,988 Summit Therapeutics shares in Q2 2026, an estimated $6.83M.
  • Tudor Investment Corp first reported a position in Summit Therapeutics in Q1 2023 and held it in 5 quarters.
  • Tudor Investment Corp's Summit Therapeutics position peaked at $7.4M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.